Evaluation of Sex Differences of Fosamprenavir (With and Without Ritonavir) in HIV-Infected Men and Women

REFERENCES

• Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivu-dine triphosphate concentrations in HIV-infected individu-als. AIDS. 2003;17(15):2159–2168.
   PubMed Web of Science ®Google Scholar
• Burger D, van der Heiden I, la Porte C, et al. Interpa-tient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin PharmacoL 2006;61(2):148–154.
   PubMed Web of Science ®Google Scholar
• van der Leur MR, Burger DM, la Porte CJ, Koopmans PP. A retrospective TOM database analysis of interpatient vari-ability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Montt. 2006;28(5):650–653.
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Jiang H, Brundage RC, et al. Sex-based dif-ferences in saquinavir pharmacology and virologic re-sponse in AIDS Clinical Trials Group Study 359. J Infect LILL 2004;189(7):1176–1184.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Pomeroy C. Sex differences in adverse re-actions to antiretroviral drugs. Top HIV Med. 2003;11(2): 55–59.
   Google Scholar
• Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J. 2006;96(8):722–724.
   PubMed Web of Science ®Google Scholar
• Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;35(1):22–32.
   PubMed Web of Science ®Google Scholar
• Gathe JC Jr, Wood R, Sanne I, et al. Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once-daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin Ther 2006;28(5):745–754.
   PubMed Web of Science ®Google Scholar
• DeJesus E. The CONTEXT study: efficacy and safety of GW433908/RTV in P1-experienced subjects with virological failure (24 week results). Paper presented at: 10th Confer-ence on Retroviruses and Opportunistic Infections; 2003; Boston, Massachusetts.
   Google Scholar
• Poirier J, Zouai O, Meynard J. Lack of effect of gender, age, weight and body mass index on trough lopinavir plasma concentrations in HIV-pretreated patients treated with Kal-etra. Paper presented at: Proceedings of the 4th Interna-tional Workshop on Clinical Pharmacology of HIV Therapy; 2003; Cannes, France.
   Google Scholar
• Robertson S, Falloon J, Formentini E, Alfaro R, Penzak S. Lack of sex-related differences in saquinavir pharmacoki-netics in an HIV seronegative cohort. Paper presented at: Proceedings of the 6th International Workshop on Clini-cal Pharmacology of HIV Therapy; 2005; Quebec City, Canada.
   Google Scholar
• la Porte C, Burger D, Gyssens I, Sprenger H, Koopmans P. Gender differences in nevirapine pharmacokinetics, fact or fiction? Paper presented at: Proceedings of the 4th In-ternational Workshop on Clinical Pharmacology of HIV Therapy; 2003; Cannes, France.
   Google Scholar
• Burger DM, Muller RJ, la Porte C, Van de Leur MR. Lopi-navir plasma levels are significantly higher in female than in male HIV-1 infected patients. Paper presented at: Pro-ceedings of the 3rd International Workshop on Clinical Pharmacology of HIV Therapy; 2002; Washington DC.
   Google Scholar
• Bongiovanni M, Bini T, Cicconi P, et al. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopi-navir/ritonavir. AIDS Res Hum Retroviruses. 2006;22(2): 132–138.
   PubMed Web of Science ®Google Scholar
• Moore AL, Kirk O, Johnson AM, et al. Virologic, immuno-logic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003;32(4):452–461.
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus dis-ease. N Engl J Med. 1995;333(12):751–756.
   PubMed Web of Science ®Google Scholar
• Cozzi Lepri A, Pezzotti P, Dorrucci M, Phillips AN, Rezza G. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and fol-lowed for up to nine years from seroconversion. Italian Seroconversion Study. BMJ. 1994;309(6968):1537–1542.
   PubMed Web of Science ®Google Scholar
• Collazos J, Asensi V, Carton JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS. 2007;21(7): 835–843.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Squires K, Kraft M, et al. Tiprananvir/ritonavir (500/200 mg bid) demonstrated potent and durable viro-logic responses and a favourable safety profile in HIV-1 positive women participating in RESIST. Paper presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007; Sydney, Australia.
   Google Scholar
• Ross L, Vavro C, Wine B, Liao Q. Fosamprenavir clini-cal study meta-analysis in ART-naive subjects: rare occurrence of virologic failure and selection of protease-associated mutations. HIV Clin Trials. 2006;7(6):334–338.
   PubMed Web of Science ®Google Scholar
• Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretro-viral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7(2):85–98.
   PubMed Web of Science ®Google Scholar
• Thiebaut R, Dequae-Merchadou L, Ekouevi DK, et al. Inci-dence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99. HIV Med. 2001;2(2):84–88.
   PubMedGoogle Scholar
• Pernerstorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS. 2001 ;15(6):725–734.
   PubMed Web of Science ®Google Scholar